

Tracker Certificate

Underlying: Disruptive Healthcare

Redemption: Open-ended

This product is not a collective investment within the meaning of the Swiss Federal Investment Fund Act and is not subject to the authorization or supervision of the Swiss Financial Market Supervisory Authority (FINMA). Investors are also exposed to the risk of insolvency of the issuer. This certificate is actively managed on a discretionary basis and has a dynamic structure.

1. PRODUCT DESCRIPTION

Certificate details

Sec. No. / ISIN / Symbol	43 698 198 / CH0436981986 / 0308BC
Issuer and Lead Manager	Banque Cantonale Vaudoise, Lausanne, Switzerland (S&P AA/stable)
Prudential supervision	BCV, Lausanne, Switzerland is subject to prudential supervision by the Swiss Financial Market Supervisory Authority (FINMA).
Paying agent	Banque Cantonale Vaudoise, Lausanne
Calculation agent	Banque Cantonale Vaudoise, Lausanne
Investment Manager	Piguet Galland & Cie SA, 41 Avenue Peschier 1206 Genève. Piguet Galland & Cie SA is subject to prudential supervision by FINMA.
Underlying asset	Basket « Disruptive Healthcare »
Management method	Discretionary and Dynamic
Conversion Ratio	1 Certificate = 1 basket
Issue volume	150 000 Certificates (includes an increase and reopening clause)
Minimum Investment	1 Certificate
Base currency	USD
Issue price	USD 100.00
Reference price	USD 100.00
Distribution fees	No distribution fees
Initial fixing date	28 September 2018
Payment date	05 October 2018
Effective termination date/ Final fixing date	Open End
Redemption date	The 6 th business day following the termination date set by either the investor or the Issuer (barring extraordinary market situations and emergencies).
Product description	<p>This USD-denominated Certificate comprises stocks of at least five companies together with a cash component (see definition below). The selection reflects the Investment Manager's investment strategy.</p> <p>The Certificate is open-ended, which means that the maturity date is not fixed at issue. The Certificate matures when either the issuer or the investor exercises his/her termination rights ("effective termination date"), subject to the notice periods set out herein.</p>
Definition of the "cash component"	<p>The cash component is an integral part of the underlying basket.</p> <p>The cash component does not pay out interest, but it could generate negative interest.</p> <p>The following currencies may be represented: USD.</p>
SSPA category	Investment product – Tracker Certificate (1300), according to the Swiss Derivative Map available at www.svsp-verband.ch



Management fees

1.00% p.a. (between 0.65% p.a. and 0.75% p.a. for the Issuer and between 0.35% p.a. and 0.25% p.a. for the Investment Manager) to be deducted on a pro rata basis from the cash component. If the amount available in the cash component is insufficient to cover the management fee, the weightings of the securities will be adjusted in order to cover this fee. Adjusting the weighting of a security, either up or down, counts as a rebalancing.

Transaction costs at rebalancing

0.10% by rebalancing calculated on the nominal rebalanced.

Stock-exchange fees and duties

When the underlying stocks are traded on an exchange that levies fees and taxes, these fees and taxes will be factored into the execution prices and will thereby affect the Certificate's performance. These fees and taxes could include a federal stamp duty or financial transaction tax.

Roles and responsibilities

The Investment Manager selects the securities in the basket, as well as the weighting of the securities and any cash component, in accordance with the investment universe and rules (see below).

The Certificate's performance therefore depends on the quality of the Investment Manager's investment decisions. The Investment Manager takes full responsibility for the composition of the basket and its impact on the Certificate's performance.

The Issuer shall execute the buy and/or sell orders necessary to issue or rebalance the Certificate on a best effort basis.

Investment universe

The stocks in the basket shall be those only of companies developing particularly innovative treatments, procedures, instruments and services in the wealth industry. The stocks must be traded on SIX Swiss Exchange or a foreign exchange recognized as having equivalent regulation.

Investors can obtain information about the investment strategy free of charge from the Investment Manager.

Management rules

1. The Investment Manager may rebalance the basket no more than 24 times per year.
2. The basket shall contain at least 5 stocks but no more than 35 stocks and a USD cash component.
3. Stocks in the basket shall be denominated in CHF, USD, EUR, GBP, SEK, NOK, DKK, JPY, HKD, SGD or AUD.
4. At least of 80% of the basket value should be invested in USD. If this percentage is not respected, the adjustment will be made at the next rebalancing.
5. The minimum market capitalization of the companies must be USD 0.5bn.
6. The cash component may not exceed 20% of the total nominal amount invested. The cash component does not pay out interest, but it could generate negative interest.
7. During a rebalancing event, the weighting of a new stock may not exceed more than half of the average daily volume traded during the last 5 days.
8. During the Certificate's lifetime, dividends (net of any taxes and fees) will be reinvested in the respective stocks.
9. Any technique intended to create a leverage in the basket is prohibited.

Investment restrictions

If a stock cannot be traded for liquidity reasons or if it is impossible to execute a transaction for technical reasons, it may take the Issuer some days to implement the Investment Manager's investment decisions. Based on these elements only, no guarantee can be made as to whether investment decisions will be implemented on the same day that instructions are received.

The Issuer reserves the right to refuse to execute a buy order if the security in question is subject to an investment restriction. Securities with an investment restriction include companies that represent a reputational risk for the Issuer and companies that are not in keeping with the Issuer's code of conduct (for instance, the Issuer does not currently invest in any company involved in cluster munitions).

If a selected security no longer complies with the investment restrictions set by the Issuer, the security must be replaced at the next rebalancing.

Basket composition

The current composition of the basket is on the last page of this document.

Changes that are unplanned or not agreed

Redemption of Certificate

Liquidity risk at the moment of redemption

Issuer's right of termination

Investor's right of termination

Termination procedure for investors

Terms and conditions

Information about any changes that are unplanned or not agreed contractually (e.g., capital transactions that affect the underlying assets such as splits, par-value reimbursements or conversions) shall be provided at www.bcv.ch/invest.

To be informed of these changes directly, you can sign up on the website and add this product to your favorites. You will then receive alerts concerning the product by email.

The redemption amount in USD will be calculated by:

- Multiplying the average price of each security at the final fixing by the quantity of each security in the basket;
- Converting securities not denominated in USD at the exchange rate set by the Issuer at the final fixing; and
- Adding the total amount remaining in the cash component.

The formula is as follows:

$$\sum_{i=1}^N n_i \times P_i \times X_i + C$$

where P_i is the average sale price of security i during the final fixing period on the reference exchange

n_i is the number of security i in the basket during the final fixing period

X_i is the exchange rate between the currency of security i and USD

N is the total number of securities in the basket

C is the amount of the cash component per Certificate

If daily liquidity strongly influences the sale of the component stocks of the Certificate, the issuer reserves the right to place sale orders over several days in order to prevent repercussions on the redemption price of the Certificate.

The Issuer has the right to terminate all Tracker Certificates in circulation at any time, but no earlier than 9 months after the issue date (please note that if the total number of Certificates in circulation falls below 2,000, the Issuer will automatically undertake redemption of all Certificates). The termination must be announced at least 1 month prior to the effective termination date. The redemption amount will be calculated on the effective termination date.

If during the product's lifetime the Certificate's price drops to 25% or below, the Issuer may also immediately terminate the Tracker Certificates without prior notice. The effective termination date shall be announced as soon as possible.

Investors may sell their Tracker Certificates on the secondary market. They also have the right to terminate any or all of the Certificates they hold provided that the Issuer has not already exercised its right of termination. The investor may do so once per quarter, on the last Tuesday of the quarter, but no earlier than 9 months after the issue date. The notice of termination must be sent to the calculation agent at least 1 month before the effective termination date, in line with the termination procedure set out below. The redemption amount will be calculated on the effective termination date.

For the investor's termination to be valid, the Issuer must not have already exercised its right of termination, and the termination notice must be received by the calculation agent at least 1 month before the effective termination date. This notice may be made via mail or email to the addresses provided under "Contact information: product redemption."

The investor's custodian bank must include the following information in its message to the calculation agent:

- name, address and clearing number
- the Tracker Certificate's security number
- the number of Tracker Certificates involved
- the effective termination date (must be at least 1 month after the notice is received by the Issuer)

The calculation agent will confirm the termination to the investor's custodian bank, specifying in particular the effective termination date.



Secondary market, Listing and Clearing

Listing, market segment

Listing will be requested on the main market of the SIX Swiss Exchange and maintained until closing on the day before the final fixing period.

Secondary market

The Issuer will operate a secondary market between 9:15 am and 5:15 pm on days when the SIX Swiss Exchange is open. The bid-ask spread will not under any circumstances exceed 3% (usually 1%), and a minimum of USD 50,000 will be offered for sale and purchase.

However, in the case of unusual market conditions or any other unforeseeable event (for example, if an exchange on which one of the stocks in the basket is listed suspends trading), the Issuer reserves the right to suspend quotations.

Trading in the Certificate will be suspended during rebalancing for a maximum of one day (i.e. a banking day from 9:15am to 5:15pm, Swiss time).

Prices are also available from Reuters, Bloomberg and SIX Telekurs.

Clearing

SIX SIS SA

Certification

The security takes the form of a book-entry security registered in the SIX SIS SA clearing system. It is not materialized, and individual securities will therefore not be printed or delivered.

Taxation

Tax disclaimer

This tax information provides only a general overview of possible tax consequences related to this product on its issue date. Laws and tax practices can change with retroactive effect.

Investors should always consult with their tax advisor for a specific evaluation of their profile before carrying out any transaction.

Switzerland

For individuals whose tax domicile is in Switzerland and who hold these investments as part of their private assets, any gains resulting from the sale of certificates are considered capital gains. Capital gains do not currently constitute taxable income.

Reinvested dividends do constitute taxable income.

The product is not subject to Swiss withholding tax, Swiss federal stamp duty or stamp duty at issue.

US tax regulations

Any income that is generated by this product and considered a "dividend equivalent payment" within the meaning of Section 871(m) of the US Internal Revenue Code may be subject to a withholding tax, pursuant in particular to the Qualified Intermediary (QI) Agreement and Foreign Account Tax Compliance Act (FATCA). BCV shall levy the tax in accordance with the terms of the legislation, and all payments arising from this product will then be made to investors net of the withheld amount. Neither BCV, nor a paying agent, nor any other third party shall be required to refund the amounts withheld on interest payments, redemptions, or any other payments arising from this product, as a result of applying Section 871(m) of the Internal Revenue Code. Investors will therefore generate less income than they would have generated without such a deduction.

Legal information

Applicable law and jurisdiction

Lausanne, Swiss law.

Prospectus

This document is not an issue prospectus within the meaning of Articles 652a and 1156 of the Swiss Code of Obligations or a simplified prospectus within the meaning of Article 5.2 of the Swiss Federal Investment Fund Act. Only the listing prospectus, which is available from BCV in French, along with any other documents required by the Regulatory Board, shall prevail.

2. PROFIT AND LOSS EXPECTATIONS

Market forecast

This Certificate is designed to take advantage of a rise in the valuation of companies included in the basket.

Potential profit

During the product's lifetime, holders of the Certificate can earn a profit if the product's market price is greater than its issue price. The potential return on the Certificate at the final fixing is comparable to the return on the underlying assets and directly depends on the quality of the investment decisions made by the Investment Manager.



Potential loss

A loss may be realized if the product is sold during its lifetime or if it is redeemed at less than the issue price at the final fixing. The product is issued in USD and includes securities denominated in foreign currencies. Decreases in the exchange rates of these currencies against the USD may cause the price of the Tracker Certificate to drop.

The Investment Manager assumes full responsibility for selecting the initial composition of the basket and for the subsequent rebalancings. The Issuer is not in any way responsible for the impact that these choices may have on the value of the Certificate or any losses that may affect investors.

Scenario

Basket Performance in USD (net of product fees)	Redemption amount (per Certificate)
25.00%	125.00
10.00%	110.00
0.00%	100.00
-5.00%	95.00
-10.00%	90.00
-25.00%	75.00

3. SIGNIFICANT RISKS INCURRED BY THE INVESTOR

Risk tolerance

The risks are comparable to those of a direct investment in the underlying basket of securities: price movements, holding-period risk, price volatility, etc.

The risks inherent in certain investments, particularly derivatives, may not be suitable for all Investors. Before conducting any transaction, investors should evaluate their risk profile and seek information from their advisor on inherent risks, and are urged to read the Swissbanking brochure "Special Risks in Securities Trading."

Issuer risk: Investors are exposed to the risk of insolvency of the Issuer, which could lead to a partial or total loss of the invested capital.

Whether an investment product retains its value does not depend solely on the performance of the underlying asset(s) but also on the solvency of the Issuer, which may change during the product's lifetime.

The rating stated in this document for the Issuer was valid at the time of issuance and may change during the product's lifetime.

Market liquidity

Under special market conditions, if the Issuer is unable to enter into hedging transactions, or if such transactions prove difficult, the spread between bid and ask prices may be temporarily expanded in order to limit the economic risks for the Issuer.

Market risk

Investors are exposed to the risks of underlying adjustment, non-convertibility, extraordinary market situations, and emergencies, such as the suspension of listing of the underlying, trading restrictions, and any other measures materially restricting the tradability of the underlying securities.

Investors are subject to the legal and contractual obligations of the markets on which the underlying is traded and on the markets that the Issuer designates or is subject to. Such market events could affect the dates and other terms and conditions contained in this document.

Currency risk

Investors whose reference currency is not the base currency for the product should be aware of the exchange-rate risk.

Adjustments

The Issuer reserves the right to adjust the composition of the Certificate in case of special events affecting one or more of the securities in the basket, including but not limited to a merger, acquisition or severe restriction on tradability. In the interests of investors, adjustments will be made in accordance with current market practices.

Important information

General information

Past performance does not guarantee present or future performance.

This document is provided for information purposes; unless otherwise stated, it is not financial analysis within the meaning of the Swiss Bankers' Association's "Directives on the Independence of Financial Research," nor is it an offer, invitation or personalized recommendation to buy or sell specific products.

The Issuer is under no obligation to acquire the underlying assets.

Subscription period

During the subscription period, the terms and conditions are for information purposes only and may be changed; the issuer is not obliged to issue this product.



Conflict of interest relating to actively managed Certificates

BCV or an entity within BCV Group may pay or receive from third parties one-time or recurrent compensation relative to this issuance or product. The contents of this document may have been used for transactions by BCV Group prior to their publication. BCV Group may hold, acquire and/or dispose of interests or positions in the components of this product.

Sales restrictions

Distribution of this document and/or the sale of this product may be subject to restrictions (e.g., USA, US persons, UK, EU, Japan, Japanese persons) and are only authorized in accordance with applicable law.

Publication date

In the event of cross-border financial services, BCV confirms that it has conducted no cross-border legal analysis. The product distributor is responsible for complying with the legal provisions in place in the country in which the product is to be distributed.

05.10.2021 revised on 07 February 2024 and 01 August 2024

Contact information

Sales team

Structured products sales team / BCV Asset Management & Trading Division

Phone

021 212 42 00

Please note that phone calls to this number may be recorded. In the event that you call us, we shall assume that you have no objections to this procedure.

Fax

021 212 13 61

Website/email

www.bcv.ch/invest / structures@bcv.ch

Mailing address

BCV / 276 - 1598 / CP 300 / 1001 Lausanne / Switzerland

Contact information – product redemption

Mailing address

BCV, Support Produits Structurés et Emissions, 283-1404, CP 300, 1001 Lausanne, Switzerland

Email address

spf@bcv.ch



Basket composition

Basket composition at 16.05.2023

Security	ISIN	Reference exchange	Currency	Weighting as %	No. of securities
Crispr Therapeutics	CH0334081137	Nasdaq	USD	3.56%	0.06694
Icon	IE0005711209	Nasdaq	USD	3.72%	0.02088
Medtronic	IE00BTN1Y115	New York	USD	4.64%	0.06054
Boston Scient.	US1011371077	New York	USD	5.89%	0.12714
CIGNA	US1255231003	New York	USD	2.58%	0.01171
CHARLES RIVER	US1598641074	New York	USD	2.98%	0.01839
Edwards Lifesciences	US28176E1082	New York	USD	4.75%	0.06221
Exact Sciences	US30063P1057	Nasdaq	USD	0.96%	0.01396
GILEAD SCIENCES	US3755581036	Nasdaq	USD	5.71%	0.08461
Globus Medical	US3795772082	New York	USD	2.12%	0.04358
HCA	US40412C1018	New York	USD	4.12%	0.01734
Illumina	US4523271090	Nasdaq	USD	1.63%	0.00939
Insulet	US45784P1012	Nasdaq	USD	6.04%	0.02189
Intuitive Surgical	US46120E6023	Nasdaq	USD	6.16%	0.02331
Iqvia Holdings	US46266C1053	New York	USD	3.77%	0.02288
Eli Lilly	US5324571083	New York	USD	3.43%	0.00915
Natera	US6323071042	Nasdaq	USD	2.90%	0.06595
Neogenomics	US64049M2098	Nasdaq	USD	2.24%	0.14532
Nuvasive	US6707041058	Nasdaq	USD	2.42%	0.06882
Stryker	US8636671013	New York	USD	6.09%	0.02472
Syneos Health	US87166B1026	Nasdaq	USD	1.72%	0.04799
10X Genomics	US88025U1097	Nasdaq	USD	3.45%	0.07661
Thermo Fisher	US8835561023	New York	USD	5.39%	0.01203
UnitedHealth	US91324P1021	New York	USD	5.38%	0.01301
Veeva Systems	US9224751084	New York	USD	3.95%	0.02735
Zoetis	US98978V1035	New York	USD	3.28%	0.02099
Poche CASH			USD	1.10%	1.28156

